TrialJournal of translational medicine2013

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.

Shingo Asahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.